Peregrine Pharmaceuticals
Unclaimed Profile

Peregrine Pharmaceuticals Reviews

Rating Trends
Recommend to a friend
Approve of CEO
Peregrine Pharmaceuticals President, CEO, and Director Steve King
Steve King
5 Ratings

Peregrine Pharmaceuticals Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Headquarters Tustin, CA
Size 150 to 499 Employees
Founded 1981
Type Company - Public (PPHM)
Industry Biotech & Pharmaceuticals
Revenue $10 to $25 million (USD) per year
Competitors Amgen, Roche

Peregrine Pharmaceuticals is spreading its wings and taking flight to attack and kill its prey: cancer and viral infections. Its clinical pipeline includes bavituximab being tested to treat pancreatic and liver cancer, as well as hepatitis C. Peregrine's other candidate, Cotara, attacks tumors from the inside out: the monoclonal antibody is loaded with radioisotopes and attaches itself to the DNA of dead and dying cells inside cancerous tissue, and then the radioisotopes bombard nearby tumor cells without harming healthy tissue. Cotara is in clinical trials for for ... More

Work at Peregrine Pharmaceuticals? Share Your Experiences

Peregrine Pharmaceuticals

Click to Rate